MedEsthetics magazines offers business education and in-depth coverage of the latest noninvasive cosmetic procedures for physicians and practice managers working in the medical aesthetics industry.
Issue link: https://medesthetics.epubxp.com/i/123304
H C Hale Cosmeceuticals Your Skin Health Company Medical Practitioners New Products for 2013 May/June 2013 $5.00 Volume 9, Number 3 medestheticsmagazine.com 20% Vitamin-C SB-7 Peels with Ferulic Acid and Tocopherol Skin Brightener • Glycolic • Salicylic • Lactic • Jessner • Mandelic • TCA • Blended • Builds collagen • Fights free radicals • Great lightener • Uses L-Ascorbic •Fights age spots •7 different lighteners •Non-comedogenic •Corrects uneven skin tones For more information: (800) 951-7005 www.halecosmeceuticals.com info@halecosmeceuticals.com See melanoma from a new perspective. See more. Know more.™ Oscar Hevia, MD Keeps His Focus on Cosmetics Clinically ambiguous PSLs pose a unique diagnostic challenge. Even with years of clinical experience, subjective impressions sometimes don't provide enough information for a clear biopsy decision. MelaFind® gives you objective data, for a different perspective on clinically ambiguous PSLs and the most curable melanomas. Examine Lesions Beneath the Surface of the Skin . Works within your current protocols Plus: HIPAA UPDATE Adding Lifestyle Services . Multi-spectral technology helps you differentiate clinically ambiguous lesions from melanoma . Enhances clinical decision making . Ultra-high sensitivity with better specificity than achievable by visualization alone—with or without a dermoscope . Clinically-tested, non-invasive, FDA-approved device Important Safety Information MelaFind® is intended to be used when a dermatologist chooses to obtain additional information for a decision to biopsy, but MelaFind® should NOT be used to confirm a clinical diagnosis of melanoma. As with all tools to provide additional information during skin exams, there is a risk that melanomas will be missed and benign moles will be biopsied. MelaFind® is indicated for use on clinically atypical cutaneous pigmented skin lesions with a diameter between 2mm and 22mm that are accessible by MelaFind®, sufficiently pigmented (ie, not for use on nonpigmented or skin-colored lesions), that do not contain a scar or fibrosis consistent with previous trauma, where the skin is intact (ie, non-ulcerated, non-bleeding lesions), that are more than 1cm away from the eye, do not contain foreign matter, and are not on special anatomic sites (ie, not for use on acral, palmar, plantar, mucosal, or subungual areas). 4PVUI#VDLIPVU4Ut4VJUFt*SWJOHUPO /: www.melasciences.com ª.&-"4DJFODFT *OD..*3FW" Learn more about MelaFind® at melafind.com/newperspective